BOSTON, Jan. 24 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced that its Chief Executive Officer, Thomas J. Bigger, will present an overview of the Company's strategy and research programs at the Piper Jaffray 17th Annual Healthcare Conference in New York City. Details of the presentation follow: Date: Wednesday, January 26, 2005 Time: 1:55 p.m. (EST) Location: The Pierre Hotel; Regency A room Speaker: Thomas J. Bigger, Chief Executive Officer Mr. Bigger's presentation will review Paratek's Tetracycline ("TET") and Multiple Adaptational Response ("MAR") Programs, as well as the Company's most recent efforts to leverage its compounds and their unique mechanisms of action in selected anti-inflammatory and neurodegenerative conditions including multiple sclerosis. A copy of the Paratek presentation will be available upon request. About Paratek Pharmaceuticals Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek's lead programs are advancing novel compounds that can circumvent or block bacterial resistance, as well as drugs that can prevent infection by interfering with Multiple Adaptational Response ("MAR") mechanisms in bacteria. Out of these efforts, Paratek has discovered a new class of antibiotics, the aminomethylcyclines, that target the need for new and potent antibacterials to overcome the problem of rapidly growing bacterial resistance. The Company's lead antibiotic clinical candidate, BAY 73-7388, the first product from this class, is being developed in a collaborative partnership with Bayer HealthCare AG for the treatment of serious infections. Outside the antibacterial therapeutic area, Paratek has also established an internal effort to exploit its novel families of compounds and their unique mechanism of action in selected anti-inflammatory and neurodegenerative conditions. Paratek has an active chemical synthesis effort to produce novel and diverse small molecules, with the goal of developing non-antibacterial products with improved activity in serious diseases based upon a growing body of clinical and basic research supporting this approach. Paratek is privately held and headquartered in Boston, Massachusetts, USA. For more information, visit Paratek's website at http://www.paratekpharm.com.
SOURCE Paratek Pharmaceuticals, Inc.